THERIVA BIOLOGICS INC (TOVX)
US87164U4094 - Common Stock
TOVX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. TOVX may be in some trouble as it scores bad on both profitability and health. TOVX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year TOVX has reported negative net income.
TOVX had a negative operating cash flow in the past year.
TOVX had negative earnings in each of the past 5 years.
In the past 5 years TOVX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -66.55%, TOVX is not doing good in the industry: 63.19% of the companies in the same industry are doing better.
TOVX has a Return On Equity (-108.35%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.55% | ||
| ROE | -108.35% | ||
| ROIC | N/A |
ROA(3y)-31.35%
ROA(5y)-67.33%
ROE(3y)-39.46%
ROE(5y)-77.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TOVX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TOVX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TOVX has been increased compared to 5 years ago.
The debt/assets ratio for TOVX is higher compared to a year ago.
2.2 Solvency
TOVX has an Altman-Z score of -12.78. This is a bad value and indicates that TOVX is not financially healthy and even has some risk of bankruptcy.
TOVX has a Altman-Z score of -12.78. This is in the lower half of the industry: TOVX underperforms 79.11% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that TOVX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, TOVX is in line with its industry, outperforming 46.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.78 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
TOVX has a Current Ratio of 2.67. This indicates that TOVX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.67, TOVX is not doing good in the industry: 69.03% of the companies in the same industry are doing better.
A Quick Ratio of 2.67 indicates that TOVX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.67, TOVX is not doing good in the industry: 67.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.87% over the past year.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
TOVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.59%
EPS Next 2Y16.4%
EPS Next 3Y13.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TOVX's earnings are expected to grow with 13.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y13.43%
5. Dividend
5.1 Amount
TOVX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
THERIVA BIOLOGICS INC
NYSEARCA:TOVX (12/20/2024, 8:04:00 PM)
After market: 1.21 +0.07 (+6.14%)1.14
-0.01 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners20.95%
Inst Owner Change-65.6%
Ins Owners0.58%
Ins Owner Change0%
Market Cap3.17M
Analysts82.5
Price Target6.12 (436.84%)
Short Float %3.11%
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-94%
PT rev (3m)50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2093.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.13 | ||
| P/tB | 0.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-29.25
EYN/A
EPS(NY)-18.87
Fwd EYN/A
FCF(TTM)-6.78
FCFYN/A
OCF(TTM)-6.76
OCFYN/A
SpS0
BVpS8.86
TBVpS8.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.55% | ||
| ROE | -108.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.35%
ROA(5y)-67.33%
ROE(3y)-39.46%
ROE(5y)-77.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.67 | ||
| Altman-Z | -12.78 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)98.02%
Cap/Depr(5y)59.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.37%
EPS Next Y7.59%
EPS Next 2Y16.4%
EPS Next 3Y13.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.45%
OCF growth 3YN/A
OCF growth 5YN/A